Bakteriyofaj Tedavisi

Yıl 2016, , 38 - 47, 15.06.2016

Demet Yaman Aydoğan H. Hüseyin Hadımlı

https://doi.org/10.35864/evmd.514172

Cited By: 1

Öz

Bakterilerin paraziti olan bakteriyofajlar, keşfedildikten sonra bakteriyel hastalıklara karşı tedavide kullanılmaya başlanmış ancak antibiyotiklerin keşfiyle, özellikle Batı ülkelerinde, faj tedavisine ilgi azalmıştır. Günümüzde antibiyotiklere karşı bakteri direncinin oluşması önemli bir sorun haline gelmiştir. Bu durum, bakteriyel hastalıkların tedavisinde ve proflakside alternatif arayışları zorunlu kılmıştır ve faj tedavisi yeniden ele alınmıştır.

Anahtar Kelimeler

Bakteriyofaj, faj, tedavi

Kaynakça

• 1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM, (2011). Phage treatment of human infections. Landes Bioscience Journals, bacteriophage,1, 66-85. http://www.landesbioscience.com/journals/bacteriophage/article/ 15845
• 2. Barrow P, Lovell M, Berchieri AO Jr, (1998). Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clinical and Diagnostic Laboratory Immunology. 5, p. 294-98.
• 3. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, B. Powell, Carlton R, Merril CR, (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin resistant Enterococcus faecium. Infect Immun.70, 204-210.
• 4. Bruttin A, Brussow H, (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents. 49, 2874-2878
• 5. Carrillo CL, Abedon ST, (2011). Pros and cons of phage therapy. Bacteriophage, 1, 111-14 http://www.landesbioscience. com/journals/bacteriophage/LocCarrilloBP1-2.pdf
• 6. Chanishvili N, Chanishvili T, Tediashvili M, Barrow PA, (2001). Phages and their application against drug resistant bacteria, J Chem Technol Biotechnol.76, 689-699.
• 7. Clark JR, March JB, (2006). Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends in Biotechnology. 24, 212-218.
• 8. Connerton PL, Loc CarrilloCM, Swift C, Dillon E, Scott A, Rees CED, Dodd CER, Frost J, Connerton IF, (2004). Longitudinal study of Campylobacter jejuni bacteriophages and their hosts from broiler chickens. Appl environ microbiol. 70, 3877-3883.
• 9. Fortier LC, Moineau S, (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Martha R. J. Clokie, Andrew M. Kropinski (eds.), Bacteriophages: Methods and Protocols, Volume 1: Isolation, characterization, and interactions, humana press, a part of springer science,business media. 501, 203-219
• 10. Fortuna W, Międzybrodzki R, Dąbrowska B, Dąbrowska W, Górski A, (2008). Bacteriophage therapy in children: Facts and prospects. Med Sci monit. 14, 126-132.
• 11. Gill JJ, Hyman P, (2010). Phage choice, isolation, and preparation for phage therapy. 11, 2-14
• 12. Gill JJ, Pacan JC, Carson ME, Leslie KE, Griffiths MW, Sabour PM, (2006a). Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob agents chemother. 50, 2912-2918
• 13. Gill JJ, Sabour PM, Leslie KE, Griffiths W, (2006b). Bovine whey proteins inhibit the interaction of Staphylococcus aureus and bacteriophage K J. Appl Microbiol. 101, 377-386 14. Goodridge LD, (2010). Designing phage therapeutics, 11, 15-27.
• 15. Gürgün V, Halkman K, (1990). Mikrobiyolojide sayım yöntemleri. Gıda Teknolojisi Derneği. Yayın no 7. http://www. mikrobiyoloji.org/TR/Genel/BelgeGoster.aspx?F6E10F88 92433CFFAAF6AA849816B2EF10F86F55954CBB47
• 16. Hanlon GW, (2007). Bacteriophages: an appraisal of their role in the treatment of bacterial infections. IJAA. 30, 118- 128.
• 17. Haq UI, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I, (2012). Bacteriophages and their implications on future biotechnology: a review. Virology Journal. (9), 1-9.
• 18. Hawkins C, Harper D, Burch D, Anggard E, Soothill J, (2010). Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Veterinary microbiology. (146) 309-313.
• 19. Hudson JA, Billington C, Carey-Smith G, Greening G, (2005). Bacteriophages as biocontrol agents in food. Journal of Food Protection, 68, 426-437
• 20. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM, (2003). Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poultry science. 82, 1108-1112.
• 21. Huff WE, Huff GR, Rath NC, Balog JM, Xie H, Moore PA, Donoghue AM, (2002). Prevention of Escherichia coli respiratory infection in Broiler chickens with bacteriophage (SPR02). Poultry Science. 81, 437-441.
• 22. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM, (2004). Therapeutic efficacy of bacteriophage and Baytril (Enrofloxacin) individually and in combination to treat Colibacillosis in broilers. Poultry science. 83, 1944-1947.
• 23. Johnson RP, Gyles CL, Huff WE, Ojha S, Huff GR, Rath NC, Donoghue AM, (2008). Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Cambridge University Press ISSN 1466-2523, Animal Health Research Reviews. 9, 201-215
• 24. Kramberger P, Honour RC, Herman RE, Smrekara F, Peterka M, (2010). Purification of the Staphylococcus aureus bacteriophages VDX-10 on methacrylate monoliths, 166, 60-64
• 25. Letarov AV, Golomidova AK, Tarasyan KK, (2010). Ecological basis for rational phage therapy. Acta naturae. 2, 60-72.
• 26. Levin BR, Bull JJ, (2004). Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology. 2, 166-173.
• 27. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen T, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S, (2003). Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φ MR11. JID. 2003, 187, 613-624.
• 28. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S, (1996). Proc. Longcirculating bacteriophage as antibacterial agents. Natl Acad Sci USA. 93, 3188-3192.
• 29. Międzybrodzki R, Fortuna W, Dąbrowska BW, Górski A, (2007). Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw. 61, 461-465.
• 30. Nakai T, Park SC, (2002). Bacteriophage therapy of infectious diseases in aquaculture. Research in Microbiology. 153, 13-18.
• 31. O’Flaherty S, Ross RP, Coffey A, (2009). Bacteriophage and their lysins for elimination of infectious bacteria. FEMS. 33, 801-819.
• 32. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ, (2007). Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol. 104, 1-13.
• 33. Park SC, Shimamura I, Fukunaga M, Mori K-I, Nakai T, (2000). Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. APPL environ microbiol. 66, 1416-1422.
• 34. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Laire MZG, Lavigne R, Huys I, Mooter GV, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R, (2011). The phage therapy paradigm: prêtàporter or surmesure? Springer Science Pharm Res. 28, 934-937.
• 35. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF, (2011). Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharmacology. 63, 1253-1264.
• 36. Sheng H, Knecht HJ, Kudva IT, Hovde CJ, (2006). Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. APPL Environ Microbiol. 72, 5359-5366.
• 37. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz- Krukowska A, (1987). Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Ex. 35: 569-583.
• 38. Smith HW, Huggins MB, (1982). Successful treatment of experimental Escherichia coli ınfections in mice using phage: its general superiority over antibiotics. J gen microbiol. 128, 307-318.
• 39. Smrekar F, Ciringer M, Peterka M, Podgornik A, Strancar A, (2008). Purification and concentration of bacteriophage T4 using monolithic chromatographic supports. J Chromatogr AnalytTechnol Biomed LifeSci. 861, 177-180.
• 40. Soothill J, Hawkins C, Anggård E, Harper D, (2004). Therapeutic use of bacteriophages. The Lancet Infectious Diseases. 4, 544-545.
• 41. Sulakvelidze A, Alavidze Z, Morris Jr JG, (2001). Bacteriophage therapy. ASM Antimicrob Agents Chemother. 45, 649-659.
• 42. Summers WC, (2001). Bacteriophage therapy. Annu Rev Microbiol. 55, 437-451.
• 43. Ustaçelebi Ş, Okuyan M, Odabaşıoğlu N, (1968). T4 R mutant bakteriyofajları ile serolojik deneyler ve normal insan serumlarının faj enfeksiyonunda stimülan etkisi. Mikrobiyoloji Bülteni. 4, 131-141.
• 44. Weber-Dabrowska B, Mulczyk M, Gorski A, (2003). Bacteriophages as an efficient therapy for antibioticresistant septicemia in man. Transplant Proc. 35, 1385-1386
• 45. Weber-Dabrowska B, Mulczyk M, Gorski A, (2001). Bacterophage therapy for infections in cancer patients. Clin Applied Immunol Rev. 1, 131-134.
• 46. Yoshida K, Nasau Y, Shitami N, Toyoda H, Takemura H, Oomori K, (2009). A novel convenient method for high bacteriophage titer assay. Oxford University Press, Nucleic Acids Symposium Series. 53, 315-316.
• 46. Lu TK, Koeris MS, (2011). The next generation of bacteriophage therapy. Current opinion in microbiology. 14, 524–31.